Clinical Trial Update: Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee [Phase 2]

View source ↗

Summary

Clinical trial update announcing a Phase 2 study to determine the optimal dose of AD-211 for osteoarthritis of the knee, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Osteoarthritis of the Knee

Drugs mentioned

• AD-211 (AD-211)

Snippet

Sponsor: Addpharma Inc. | Conditions: Osteoarthritis of the Knees | Phase 2 | Status: NOT_YET_RECRUITING